Our Stocks to Watch today include China America Holdings (OTCBB: CAAH), Copper King Mining Corporation (OTC: CPRK), SigmaTel, Inc. (NASD: SGTL), Smith Investment Company (OTC: SMIC), DNAPrint Genomics, Inc. (OTCBB: DNAG)
Visit http://www.otcpicks.com/ to register for our Daily Market Mover’s Digest Newsletter, and Email Stock Watch Alerts.
CHINA AMERICA HOLDINGS INCORPORATED (OTCBB: CAAH)
Detailed Quote: http://www.otcpicks.com/quotes/CAAH.php
Company Profile: http://www.otcpicks.com/china-america/china-america.htm
China America Holdings, Inc.™ (CAAH) is a diversified Global Holdings Company with operations in the U.S. and China. China America Holdings has three operating divisions.
Shanghai Aohong Chemical Co,, based in Shanghai, China, a distributor of assorted liquid coolants which are utilized in a variety of applications, primarily as refrigerants in air conditioning systems for automobiles, residential and commercial air conditioning systems, and a manufacturer of steel non-refillable cylinders. For more information, please visit the Shanghai Aohong website.
Big Tree Toys, Inc, based in Shantou, China, is an authorized agent for thousands of toy manufacturers in China. Big Tree represents over 8,000 toy manufacturers. Our product offerings include in excess of 180,000 varieties of toy products including remote control toys, digital toys, sports toys, play sets, educational toys, dolls, and infant toys. Big Tree Toys simplifies sourcing products from China. For more information, please visit Big Tree Toys USA and Big Tree Toys website.
Sense Technologies, Inc., based in Ft. Lauderdale, FL, is a leading provider of biometric solutions, and micro-sensor identification systems. Sense develops products targeting Homeland Security, and offers solutions that improve and secure many business, military, and personal processes. Sense owns patents and intellectual property for an MEMS based explosives detection technology licensed through a national government laboratory.
CAAH News:
February 4 - China America Holdings, Inc. Sees Profitability in 2008 as Revenue from Chinese Subsidiaries Continues to Expand
China America Holdings, Inc. (OTCBB: CAAH), a diversified holding company operating in both the United States and China, updated today the company's business outlook for 2008.
Throughout 2007, management began transitioning the company by diversifying its operations through strategic acquisitions in China in an effort to increase revenue and move the company toward a profitable future. The company was able to make two key acquisitions in China in 2007 and also changed its name to China America Holdings, Inc. in order to more accurately reflect its new business objective.
China America Holdings begins 2008 with two majority owned China based subsidiaries. The first, Shanghai Aohong Industry Company, Limited (“Aohong”), a leading distributor of chemical fluorine products throughout Asia, is 56% owned by our company. Aohong specializes in the processing, distribution, and import/export of a variety of refrigerant and coolant products used in automobiles, air conditioning systems, refrigeration units, and fire extinguishing agents. The second, Big Tree Toys, Inc., a Chinese Toy sourcing and exporting company located in Shantou, China, is 60% owned by our company. Big Tree Toys specializes in sourcing, quality control and logistics in the toy and entertainment related industry in China with over 100,000 toys and entertainment related products. In addition, the company continues to develop and market its biometric and explosive detection products.
Management intends to continue its rapid growth over the next several years through a combination of the expansion of its current operations as well as our continued focus on making accretive acquisitions. Management now anticipates that 2008 will be a record year for the company both in revenue and more importantly in achieving its first profitable year of operations. Based on the company’s preliminary review of our business outlook for 2008 management sees revenue for China America Holdings, Inc. exceeding $50 million and anticipates net income will exceed $1.2 million.
Mr. Dore Perler, Chairman and CEO of China America Holdings, stated: “We enter 2008 in the best position in our company’s history. Our current China based subsidiaries are poised to grow their operations substantially as we expand our existing product lines through the introduction of innovative new products and business solutions for our current customers, as well as continue to add new customers to our growing sales base. We remain committed to our business plan of making accretive acquisitions that we believe will create high-margin revenue opportunities for our company. We are currently evaluating a number of potential acquisition candidates that we believe may be highly complementary to our existing businesses and we intend to aggressively pursue those opportunities in the future.”
COPPER KING MINING (OTC: CPRK)
Detailed Quote: http://www.otcpicks.com/quotes/CPRK.php
Company Profile:
http://www.otcpicks.com/copper-king-mining/copper-king-mining.htm
Copper King Mining Corporation currently owns approximately 1200 acres in the Drum Mountains of Utah, which are patent deeded mining claims which contain gold, silver and copper. The company recently added to its holdings by filing six more claims on land which was inside their holdings, but not patent deeded. Contiguous to that acreage is approximately 1100 acres of claims filed by Western Utah Copper Company. As the companies explored the concept of a joint venture on the Drum Mountain properties, it was decided that a very viable consideration was to join the total assets of both companies.
CPRK News:
February 4 - Copper King Mining Corporation Anticipates the Completion of Its Ball Mill Complete with Floatation for Production of Copper Concentrate That Will Contain Commercial Amounts of Gold, and Silver
Copper King Mining Corporation (OTC: CPRK) announced that construction is going forward as scheduled on it’s mill near Milford Utah. Construction began in 2007 of a Ball / Floatation Mill which when completed will have the capacity to process 2500 short tons of ore per day. Based on that figure and on current ore values being recovered the mill should be able to concentrate upwards of 65,000 lbs of copper per day with substantial gold and silver contained in the concentrate. It is anticipated that the mill could come on line in the 2nd quarter of 2008.
Interested parties may view photos and video of the patent deeded areas owned by Copper King Mining Corporation at http://www.thecopperkings.com/ and assets owned and controlled by Western Utah Copper Company at http://www.westernutahcopper.com/.
SIGMATEL INCORPORATED (NASD: SGTL)
"Up 59.50% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SGTL.php
SigmaTel, Inc., a fabless semiconductor company, engages in the design, development, and marketing of analog-intensive mixed-signal integrated circuits (ICs) in the United States, Taiwan, China/Hong Kong, and Singapore. It offers system-level solution, including highly-integrated ICs, customizable firmware, software development tools, reference designs, and applications support. The company provides its ICs for various digital multimedia products in the consumer electronics markets, including digital media players, printers, and digital televisions. SigmaTel markets its products to original equipment manufacturers and original device manufacturers through independent sales representatives and distributors. The company was founded in 1993 and is headquartered in Austin, Texas.
SGTL News:
February 4 - SigmaTel Enters into Definitive Agreement to Be Acquired by Freescale
SigmaTel's Analog and Mixed-Signal IC Products to Complement Freescale's Multimedia Portfolio
SigmaTel, Inc. (NASD: SGTL) and Freescale Semiconductor today announced that they have entered into a definitive agreement for Freescale to acquire SigmaTel. Freescale is a privately held, global leader in the design and manufacture of embedded semiconductors. SigmaTel is a leading provider of analog intensive, mixed-signal integrated circuits (ICs) for the digital multimedia market.
Under the terms of the agreement, Freescale will pay $3.00 cash per outstanding share of SigmaTel stock, or approximately $110 million in total. Vinson & Elkins L.L.P. acted as the legal advisor to SigmaTel and ThinkEquity Partners LLC, a wholly owned subsidiary of London based Panmure Gordon & Co., acted as exclusive financial advisor to SigmaTel.
The agreement contains a “go-shop” provision through March 4, 2008, during which period SigmaTel has the right to solicit and engage in discussions and negotiations with respect to potential competing proposals. The agreement is subject to various customary closing conditions, including all necessary shareholder and regulatory approvals, and is expected to close in the second quarter of 2008.
“The increased demand for feature rich, always-connected consumer electronics devices is driving manufacturers to look for platform-based solutions that will accelerate time to market,” said Phil Pompa, president and CEO of SigmaTel. “With the addition of SigmaTel, Freescale is the obvious choice for these next-generation devices."
“The SigmaTel acquisition enhances the long-term, strategic value we can deliver to our customers,” said Lynelle McKay, senior vice president and general manager of Freescale's Networking and Multimedia Group. “Freescale’s proven strengths in the high-performance multimedia and general purpose markets are complemented by SigmaTel’s strong mixed-signal expertise in the portable media player and consumer audio markets.”
For more information on SigmaTel, please visit http://www.sigmatel.com/.
SMITH INVESTMENT COMPANY (OTC: SMIC)
"Up 48.44% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SMIC.php
Smith Investment is a diversified company with headquarters in Milwaukee, Wisconsin. Its product lines include multicolor printing and related services and commercial warehousing, trucking and packaging. The company also owns a control position in A. O. Smith Corporation (NYSE: AOS).
SMIC News:
February 4 - Smith Investment Company Proposes Restructuring of Holdings in A. O. Smith Corporation
Smith Investment Company (OTC: SMIC) announced that it has made a proposal to restructure its holdings in A. O. Smith Corporation (NYSE: AOS). The proposed transaction would result in the shareholders of Smith Investment having direct ownership of the same number and type of A. O. Smith shares currently held by Smith Investment. Smith Investment's common stock has been valued at a significant discount to the underlying value of the A. O. Smith shares held by Smith Investment. The proposed transaction is intended to allow Smith Investment's shareholders to realize the underlying value of Smith Investment's holdings in A. O. Smith and provide enhanced liquidity to Smith Investment's shareholders.
Pursuant to the proposed transaction, Smith Investment would be merged with a newly formed subsidiary of A. O. Smith. In the merger, Smith Investment's common stock would be exchanged for newly issued shares of A. O. Smith's class A common stock and common stock. It is intended that this exchange would be non-taxable to the shareholders of Smith Investment. Because the total number and type of A. O. Smith shares issued in the proposed transaction would equal the number and type of A. O. Smith shares currently held by Smith Investment, there would be no net change to the number of outstanding A. O. Smith shares. Prior to the merger, Smith Investment intends to distribute in a taxable transaction substantially all of its assets (other than its holdings in A. O. Smith) to the shareholders of Smith Investment. The proposal also contemplates that, prior to the merger, substantially all of Smith Investment's pre-closing liabilities would be discharged or assumed by the entity or entities in which Smith Investment's distributed assets are held.
A special committee comprised of two independent directors from Smith Investment's board of directors recommended the making of the proposal. The Smith Investment special committee was formed to consider possible transactions on behalf of the shareholders of Smith Investment other than certain members of the Smith family and trusts for the benefit of certain members of the Smith family. The Smith Investment special committee has engaged independent financial and legal advisors to assist it in completing its review. Smith Investment's board of directors has agreed that it will not approve any transaction without the prior recommendation of the Smith Investment special committee.
Before recommending the proposal, the Smith Investment special committee consulted with certain Smith Investment shareholders holding in the aggregate a majority of Smith Investment's common stock. These shareholders separately indicated to the Smith Investment special committee that they would support a transaction on substantially the terms proposed. These shareholders also separately indicated to the Smith Investment special committee that they would not support any alternative transaction that resulted in a sale of Smith Investment or otherwise eliminated or limited the dual class voting structure at A. O. Smith.
Smith Investment indicated that the proposal is preliminary, and remains subject to negotiation of definitive documentation and approval of the Smith Investment special committee and board of directors. The proposal also requires the approval of the A. O. Smith board of directors. A. O. Smith has not yet had an opportunity to respond to the proposal. There can be no assurance that the proposed transaction or any other transaction will result from the proposal. Except if required by applicable law, Smith Investment does not intend to comment further on the proposal unless and until a definitive agreement with respect to a proposed transaction has been reached.
DNAPRINT GENOMICS (OTCBB: DNAG)
"Up 14.29% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/DNAG.php
DNAPrint Genomics, Inc. engages in the research and development of genomic products, and provides scientific services and tests to the genealogy, forensic, pharmaceutical, and genetics markets in the United States. Its primary product under development is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients. The company's other products under development include PT-501 for the treatment of attention deficit hyperactivity disorder; PT-502 for the treatment of drug addiction; and PT-503 for the treatment of depression. DNAPrint Genomics also develops diagnostic tests, including OVANOME for ovarian cancer, STATINOME for the safety of statins, DIABETES-CD59 for pre-diabetes diabetic complications; and PONV for post-operative nausea and vomiting. In addition, it offers DNAWitness product suite for the forensics market to determine genetic heritage from DNA samples obtained from crime scenes; and ANCESTRYbyDNA and EURO-DNA, which are genealogy products that provide an inference of an individual's genetic ancestry or heritage. Further, the company provides sequencing and genotyping services to industrial customers. DNAPrint Genomics has strategic alliances with Moffitt Cancer Center, and Beth Israel Deaconess Medical Center; and a collaborative research agreement with Beth Israel. It also has a license agreement with Harvard Medical School, and a research sponsorship agreement with Massachusetts College of Pharmacy and Health Sciences. The company, formerly known as Lexington Energy, Inc., was incorporated in 1983 and is based in Sarasota, Florida.
DNAG News:
February 1 - Nanobac Pharmaceuticals Inc. Signs LOI for the Acquisition of DNAPrint Genomics
Nanobac Pharmaceuticals Inc. (OTCBB: NNBP) ("Nanobac" or "the Company”) announced a jointly signed letter of intent for the acquisition of DNAPrint Genomics, Inc. (OTCBB: DNAG) (“DNAPrint” or DNAP). With the acquisition, which is subject to DNAPrint Genomics shareholder approval, Nanobac becomes one of a select group of next-generation drug and diagnostics developers, applying advanced computational methods and systematic genome-based approaches to streamline clinical product development. Nanobac adds advanced drug and diagnostics development programs, key patents and patent applications, and a proprietary product modeling platform to its existing initiatives, and expands its focus into multiple disease sites for both Diagnostics and Therapeutics.
The combined company would have annualized revenue of approximately $5,000,000, developing drug pipeline and product development collaborations with Harvard/Beth Israel Deaconess Medical Center, Mayo Clinic, Cleveland Clinic and Emory University.
DNAPrint Genomics has developed, patented and published various technologies for an improved, 21st century model of clinical product development - aimed at maximizing effectiveness, minimizing unintended effects, reducing costs and shifting the risk to reward ratio during clinical product development. These tools include extensively validated and published genome assays for individualized assessments of genetic ancestry on multiple levels (consumer products segment), tools for the inference of physical characteristics for the forensics market, tools for the inference of patient proclivities to respond to treatments (pharmacogenomics) and meta-analytical systems for computationally modeling the biology of clinical products for a more intelligent approach to drug and diagnostic development. DNAG's primary objective has been, and Nanobac's primary objective will be, to develop progressive theranostics drugs, which combine extensively modeled drugs with genomics-derived intelligence to create more economical and powerful drug/test combination products with superior performance parameters. DNAG's flagship product, PT-401, is expected to result in more effective treatment of anemia, and its Protectin(TM) (CD-59) diagnostic test is expected to allow patients and their physicians to more effectively manage the risks and treatment decisions for diabetes. DNAG supports its clinical programs, in part, through the sale of consumer genetics tests genotyping services on a contractual basis.
“Dr Hector Gomez has been on the Company’s advisory board giving Nanobac the benefit of evaluating DNAG’s technologies and portfolio of products,” said Dr. Benedict Maniscalco, Co-Chairman and Chief Medical Officer of Nanobac Pharmaceuticals. “Combining our diagnostic portfolios, specifically DNAP’s Protectin™ and Nanobac’s NB2 has the potential to play a significant role in the early diagnosis of vascular disease and could potentially help in identifying early signs and progression of cardiovascular disease,” Dr. Maniscalco concluded.
"The Protectin(TM) test will be used to identify diabetics at risk of developing vascular complications," said Dr. Gomez, Chairman of DNAP. "Protectin(TM) is anticipated to become a new tool in the complex understanding of Diabetes and could potentially replace HbA1c, the current test used to evaluate glucose control. Combined with Nanobac's diagnostic portfolio, Protectin(TM) is expected to dramatically increase the physician's ability to diagnose patients at significant cardiovascular risk," concluded Dr. Gomez.
According to Global Industry Analysts, the international global diabetes diagnostic supplies market is expected to grow to US$15.4 billion by 2010. This indicates significant potential for the Protectin™ test. Additionally, cardiovascular diagnostics will see a high rate of growth also, increasing from $11.9 billion in 2007 to $21.4 billion by the end of 2012. The cardiovascular diagnostics market represents one of the largest sectors within the diagnostics industry, chiefly due to the high prevalence rate of and high mortality rate from cardiovascular disease.
DNAG’s flagship PT-401 therapeutic, in pre-clinical stages, is a genetically engineered erythropoietin dimmer (double form), which elicits a heartier, longer lasting increase in hematocrit for anemic patients. The singlet form of erythropoietin was introduced by Amgen Corporation in 1989, and enjoys a $2B in annual sales. A successfully approved PT-401 alternative is expected to allow physicians to treat patients with less drug and at less frequent intervals, at significant savings, while at the same time, increasing the consistency of therapeutic response.
Nanobac Pharmaceuticals is the leader in research and treatment of degenerative diseases stemming from nanobacterial infections. This infection is implicated in the formation of disease-causing calcification and plaque in the circulatory system and vital organs. Nanobac Pharmaceuticals markets diagnostics and prescription nanobiotic medications demonstrated to safely and effectively treat an underlying cause of atherosclerosis, coronary heart disease and other degenerative diseases.
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit the company’s website at http://www.nanobac.com/.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover’s Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated ten thousand dollars by a third Party (StockPromoters.com) for CAAH advertising and promotional services. OTCPicks.com has been compensated sixteen thousand five hundred dollars by a third party for CPRK advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
